Mark Espeland to Sample Size
This is a "connection" page, showing publications Mark Espeland has written about Sample Size.
Connection Strength
0.032
-
Marx N, Rosenstock J, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Espeland MA, Bluhmki E, Mattheus M, Ryckaert B, Patel S, Johansen OE, Woerle HJ. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®). Diab Vasc Dis Res. 2015 May; 12(3):164-74.
Score: 0.032